Figure 1.

Different strategies of T cell immunotherapies. (A) Isolation of tumor-infiltrating lymphocytes from patient tumor followed by expansion of anti-tumor T cells in vitro and infusion back to the patients. (B) Generation of antigen-presenting cells from monocytes derived from patient PBMC and loaded with potential antigens derived from the mutational and immunopeptidome analysis of patient tumor. The antigen-loaded APC are co-cultured with autologous T cells that are screened for anti-tumor T cells and further expanded. (C) TCR is cloned and used to gene-engineer TCR in fresh autologous or allogeneic T cells for expansion in laboratory conditions and infusion back to the patient. (D) Isolation of T cells from patient or allogeneic donor and gene-editing approaches for engineering of chimeric antigen receptors targeting cancer cells.